` 2552 (Hua Medicine) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

H
2552
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Hua Medicine has significantly outperformed Hang Seng (Hong Kong), delivering a return of +75% compared to the Hang Seng (Hong Kong)'s +21% growth.

Stocks Performance
2552 vs Hang Seng (Hong Kong)

Loading
2552
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2552 vs Hang Seng (Hong Kong)

Loading
2552
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
2552 vs Hang Seng (Hong Kong)

Loading
2552
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Hua Medicine vs Peers

Hang Seng (Hong Kong)
2552
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Hua Medicine
Glance View

Market Cap
3.8B HKD
Industry
Pharmaceuticals

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.

Intrinsic Value
7.41 HKD
Undervaluation 52%
Intrinsic Value
Price HK$3.58
H
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett